Regular plasma HIV-RNA testing for persons living with HIV on antiretroviral therapy (ART) is now the global standard, but as many as 60% of persons in Africa today on ART do not have access to standa
Samples acquired as indicated in various geographical locations; nd: data not available; viral load test was estimated by approved clinical laboratory methods (Amplicor HIV assay Roche or bDNA Bayer);
Extracted genomic nucleic acid at 2.2 ng/µL was in all samples except the negative control and HIV-positive control. In this comparison, samples and controls assayed by the non-instrumented nucleic ac
Viral load (VL) measurements are critical to the proper management of HIV in developing countries. However, access to VL assays is limited by the high cost and complexity of existing assays. While the
